Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

AstraZeneca plc. (10/17/13). "Press Release: AstraZeneca Announces »Open Innovation« Research Collaboration with Taiwan’s Research Program for Biopharmaceuticals". Taipei.

Region Region Taiwan (ROC)
Organisations Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Organisation 2 Taiwan (govt)
Products Product drug discovery
  Product 2 biopharmaceutical
Person Person Frail, Don (AstraZeneca 201310 VP + Head of Emerging Innovations, Science Partnerships + Alliances)
     


AstraZeneca and Taiwan's National Research Program for Biopharmaceuticals (NRPB) today announced a collaborative programme to support academic research proposals using 'open innovation' as a catalyst for drug discovery. The programme will connect expert physicians and scientists with a wide range of high-quality, small molecule compounds and biologics developed by AstraZeneca.

Successful research proposals submitted from academic institutes in Taiwan will be funded by the NRPB to explore new therapeutic uses for specific AstraZeneca compounds which may in turn lead to the development of novel therapies for patients. Further financial details were not disclosed. Areas of high interest include cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

"This initiative is another important step in the new era of medical discovery via open innovation and public-private collaboration." said Dr. Michael M.C. Lai, Director of NPRB. "NRPB is delighted to be partnering with AstraZeneca in this exciting approach towards the development of new treatments for patients and the advancement of medical science in Taiwan. We expect other domestic and international biopharmaceutical companies will follow this example."

"By giving best-in-class academic research institutions access to some of our valuable, high-quality compounds, we are opening doors to unexplored areas of pre-clinical and clinical research to help find the next generation of medical breakthroughs," said AstraZeneca's Don Frail, Vice President and Head, Emerging Innovations, Science Partnerships and Alliances.

Some medical compounds do not prove effective for the specific use for which they were developed. However, if additional research is conducted, they may succeed for different therapeutic uses. Also, some medical compounds with existing, proven benefits may also be found to have additional and sometimes unrelated uses after further research. This agreement provides a framework that will enable researchers to access a defined collection of AstraZeneca candidate drugs and their related data to enable such additional pre-clinical and clinical studies.

The collaboration also brings together complementary skills that will help researchers harness and foster medical innovation: NRPB's and academic thought-leaders' insights that will propose and accelerate the investigation of innovative hypotheses and technologies; AstraZeneca via its proven track record in global research and drug discovery.

~ Ends ~


NOTES TO EDITORS


About Biopharmaceutical Open Innovation

By sharing new ideas and enabling scientific innovation to cross boundaries between biopharmaceutical companies, academia, government and non-profit organisations, Open Innovation can accelerate new ideas, disease knowledge and new uses for innovative medicines. The increased complexity of the scientific, regulatory and operating environments for all stakeholders engaged in addressing today's pressing global health challenges means they can no longer afford to work in silos. Open Innovation encourages everyone involved to share, discuss and develop ideas in a flexible environment that acknowledges the value of collaborative thinking. By creating a more permeable research environment, Open Innovative can expand the advancement of medical science and make effective use of resources.


About NRPB

NRPB aims to strengthen the capability of the midstream function of the biopharmaceutical development pipeline in Taiwan; through the validation of preclinical testing and clinical trials, fulfilling the vision of commercializing scientific outcomes. The mid-term goal is to strengthen IP management and promote industrial bridging. The long-term goal is to train Taiwan scientists and foster domestic industries for excellence and international competitiveness, and to promote domestic innovations and achievements onto the world stage. NRPB funding agencies include National Science Council, Ministry of Economic Affairs, Department of Health, and Atomic Energy Council. NRPB participating organizations include Development Center for Biotechnology, National Health Research Institutes and Center for Drug Evaluation. For more information please visit: www.nrpb.sinica.edu.tw/


About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com


Media Enquires

AstraZeneca
Vince Docherty +852 9470 5983 (Asia/Global)
Laura Woodin +1 30 2885 1087 (US/Global)

NRPB
Ling Tsui +886 2655 8233 (Taiwan)

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top